Compare
Nautilus Biotechnology, Inc. vs 908 Devices Inc. vs EyePoint, Inc. vs Quanterix Corp
| Latest fiscal year | Nautilus Biotechnology, Inc. NAUT | 908 Devices Inc. MASS | EyePoint, Inc. EYPT | Quanterix Corp QTRX |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | $56.20M | $31.37M | $138.90M |
| Revenue growth (YoY) | n/a | +17.7% | -27.5% | +1.1% |
| Gross margin | n/a | 50.6% | n/a | 46.8% |
| Operating margin | n/a | -70.1% | -776.0% | -90.4% |
| Net margin | n/a | 34.7% | -739.4% | -77.1% |
| Net income | -$59.00M | $19.49M | -$231.96M | -$107.15M |
| EPS (Diluted) | -$0.47 | $0.54 | -$3.17 | -$2.51 |
| Operating cash flow | -$50.70M | -$23.69M | -$240.11M | -$77.24M |
| Free cash flow | -$51.97M | -$24.64M | -$243.39M | -$79.85M |
| Cash & equivalents | $12.39M | $70.52M | $101.82M | $29.84M |
| Total assets | $191.11M | $190.07M | $364.00M | $418.77M |
| Total liabilities | $34.14M | $46.37M | $57.88M | $123.04M |
| Shareholders' equity | $156.97M | $143.70M | $306.11M | $295.73M |
| Return on year-end equity | -37.6% | 13.6% | -75.8% | -36.2% |
| Shares outstanding | 126.47M | 36.32M | 82.83M | 46.74M |
Revenue, most recent five fiscal years
| Fiscal year | Nautilus Biotechnology, Inc. | 908 Devices Inc. | EyePoint, Inc. | Quanterix Corp |
|---|---|---|---|---|
| Latest | n/a | $56.20M Ended 2025-12-31 | $31.37M Ended 2025-12-31 | $138.90M Ended 2025-12-31 |
| 1 year earlier | n/a | $47.75M Ended 2024-12-31 | $43.27M Ended 2024-12-31 | $137.42M Ended 2024-12-31 |
| 2 years earlier | n/a | $50.23M Ended 2023-12-31 | $46.02M Ended 2023-12-31 | $122.37M Ended 2023-12-31 |
| 3 years earlier | n/a | $46.85M Ended 2022-12-31 | $41.40M Ended 2022-12-31 | $105.52M Ended 2022-12-31 |
| 4 years earlier | n/a | $42.21M Ended 2021-12-31 | $36.94M Ended 2021-12-31 | $110.56M Ended 2021-12-31 |